178 related articles for article (PubMed ID: 7696112)
41. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial.
Hayashi M; Tsuchiya Y; Itaya Y; Takenaka T; Kobayashi K; Yoshizawa M; Nakamura R; Monkawa T; Ichihara A
Nephrol Dial Transplant; 2004 Aug; 19(8):2067-73. PubMed ID: 15187195
[TBL] [Abstract][Full Text] [Related]
42. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
43. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
[TBL] [Abstract][Full Text] [Related]
44. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
Slatopolsky E; Finch J; Ritter C; Takahashi F
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
[TBL] [Abstract][Full Text] [Related]
45. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
[TBL] [Abstract][Full Text] [Related]
46. Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.
Martin KJ; González EA; Gellens ME; Hamm LL; Abboud H; Lindberg J
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S61-6. PubMed ID: 9808145
[TBL] [Abstract][Full Text] [Related]
47. Pulse oral versus pulse intraperitoneal calcitriol: a comparison of efficacy in the treatment of hyperparathyroidism and renal osteodystrophy in peritoneal dialysis patients.
Gadallah MF; Arora N; Torres C; Ramdeen G; Schaeffer-Pautz A; Moles K
Adv Perit Dial; 2000; 16():303-7. PubMed ID: 11045316
[TBL] [Abstract][Full Text] [Related]
48. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
49. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
Schömig M; Ritz E
Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
[TBL] [Abstract][Full Text] [Related]
50. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis.
Dunlay R; Rodriguez M; Felsenfeld AJ; Llach F
Kidney Int; 1989 Dec; 36(6):1093-8. PubMed ID: 2601258
[TBL] [Abstract][Full Text] [Related]
51. Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism.
Fischer ER; Harris DC
Clin Nephrol; 1993 Oct; 40(4):216-20. PubMed ID: 8261678
[TBL] [Abstract][Full Text] [Related]
52. A crossover comparison of intermittent oral and intravenous administration of calcitriol on the parathyroid hormone concentration in hemodialysis patients.
Peng SJ; Yang CS; Ferng SH; Chen LY
Miner Electrolyte Metab; 1997; 23(1):13-8. PubMed ID: 9058364
[TBL] [Abstract][Full Text] [Related]
53. [Pulsed doses of calcitriol in the treatment of secondary hyperparathyroidism in patients on hemodialysis].
Sotorník I; Petrásek R; Schück O; Adamec M; Smrcková I; Tocík J
Vnitr Lek; 1997 Sep; 43(9):584-91. PubMed ID: 9750467
[TBL] [Abstract][Full Text] [Related]
54. Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients.
Rolla D; Paoletti E; Marsano L; Mulas D; Peloso G; Cannella G
Perit Dial Int; 1993; 13(2):118-21. PubMed ID: 8494932
[TBL] [Abstract][Full Text] [Related]
55. Abnormal calcaemic response to PTH in the uraemic rat without secondary hyperparathyroidism.
Berdud I; Martin-Malo A; Almaden Y; Tallon S; Concepcion MT; Torres A; Felsenfeld A; Aljama P; Rodriguez M
Nephrol Dial Transplant; 1996 Jul; 11(7):1292-8. PubMed ID: 8672025
[TBL] [Abstract][Full Text] [Related]
56. Secondary hyperparathyroidism in CAPD patients: its suppressibility with high doses of calcitriol.
Felipe C; Miranda B; Selgas R; Martinez ME; Miguel JL; Moreno F; Caparros G; Torre A; Sicilia LS
Adv Perit Dial; 1990; 6():238-41. PubMed ID: 1982816
[TBL] [Abstract][Full Text] [Related]
57. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
58. Effect of percutaneous calcitriol injection therapy on secondary hyperparathyroidism in uraemic patients.
Shiizaki K; Negi S; Mizobuchi M; Hatamura I; Narukawa N; Sakaguchi T; Kitabata Y; Sumikado S; Akizawa T
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii42-6. PubMed ID: 12771299
[TBL] [Abstract][Full Text] [Related]
59. Vitamin D receptor genotype influences parathyroid hormone and calcitriol levels in predialysis patients.
Marco MP; Martínez I; Amoedo ML; Borràs M; Saracho R; Almirall J; Fibla J; Fernández E
Kidney Int; 1999 Oct; 56(4):1349-53. PubMed ID: 10504487
[TBL] [Abstract][Full Text] [Related]
60. Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Huang TP; Shieh SD; Akmal M
Miner Electrolyte Metab; 1994; 20(3):97-102. PubMed ID: 7816008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
